Imperfect biomarkers for adjuvant chemotherapy in early stage breast cancer with good prognosis
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Social Science & Medicine
- Vol. 246, 112735
Abstract
No abstract availableKeywords
Funding Information
- Institut National Du Cancer
This publication has 33 references indexed in Scilit:
- How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and GynecopathologistsPLOS ONE, 2012
- Regulating diagnosis in post-genomic medicine: Re-aligning clinical judgment?Social Science & Medicine, 2011
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Oncology Practice, 2007
- Constructing a Representation for an Ecology of KnowledgeSocial Studies of Science, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Cultural studies of biomedicine: An agenda for researchSocial Science & Medicine, 1995
- Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast CancerSeminars in Thrombosis and Hemostasis, 1991
- Editorial: Woods or Trees? Ideas and Actors in the History of ScienceIsis, 1988
- Plasminogen activator and cancerEuropean Journal of Cancer and Clinical Oncology, 1984